CA2531492A1 - Compositions for purifying and crystallizing molecules of interest - Google Patents

Compositions for purifying and crystallizing molecules of interest Download PDF

Info

Publication number
CA2531492A1
CA2531492A1 CA002531492A CA2531492A CA2531492A1 CA 2531492 A1 CA2531492 A1 CA 2531492A1 CA 002531492 A CA002531492 A CA 002531492A CA 2531492 A CA2531492 A CA 2531492A CA 2531492 A1 CA2531492 A1 CA 2531492A1
Authority
CA
Canada
Prior art keywords
molecule
interest
ligand
coordinating moiety
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002531492A
Other languages
English (en)
French (fr)
Inventor
Guy Patchornik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affisink Biotechnology Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2531492A1 publication Critical patent/CA2531492A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002531492A 2003-07-24 2004-07-22 Compositions for purifying and crystallizing molecules of interest Abandoned CA2531492A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL15708603A IL157086A0 (en) 2003-07-24 2003-07-24 Multivalent ligand complexes
IL157086 2003-07-24
PCT/IL2004/000669 WO2005010141A2 (en) 2003-07-24 2004-07-22 Compositions for purifying and crystallizing molecules of interest

Publications (1)

Publication Number Publication Date
CA2531492A1 true CA2531492A1 (en) 2005-02-03

Family

ID=32652285

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002531492A Abandoned CA2531492A1 (en) 2003-07-24 2004-07-22 Compositions for purifying and crystallizing molecules of interest

Country Status (13)

Country Link
US (1) US20060121519A1 (cg-RX-API-DMAC7.html)
EP (1) EP1648995A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007515384A (cg-RX-API-DMAC7.html)
KR (1) KR20060037337A (cg-RX-API-DMAC7.html)
CN (1) CN101415721A (cg-RX-API-DMAC7.html)
CA (1) CA2531492A1 (cg-RX-API-DMAC7.html)
IL (2) IL157086A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06000944A (cg-RX-API-DMAC7.html)
NO (1) NO20060400L (cg-RX-API-DMAC7.html)
RU (1) RU2006105648A (cg-RX-API-DMAC7.html)
SG (1) SG145760A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005010141A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200600315B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7956165B2 (en) 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
WO2006085321A2 (en) * 2005-02-10 2006-08-17 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8163886B2 (en) * 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2009064425A1 (en) * 2007-11-13 2009-05-22 Rational Affinity Devices, L.L.C. Multistate affinity ligands for the separation and purification of antibodies, antibody fragments and conjugates of antibodies and antibody fragments
CA2708836A1 (en) * 2007-12-17 2009-06-25 Affisink Biotechnology Ltd. Methods for purifying or depleting molecules or cells of interest
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
DK2370561T3 (da) 2008-12-16 2019-10-21 Emd Millipore Corp Omrøringstankreaktor og fremgangsmåde
KR101855714B1 (ko) 2010-03-05 2018-05-10 베링거 인겔하임 인터내셔날 게엠베하 항체의 선택적 농축
CN102892791B (zh) 2010-05-17 2017-05-17 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
US10030224B2 (en) 2015-11-01 2018-07-24 Ariel-University Research And Development Company Ltd. Methods of analyzing cell membranes
WO2021152584A1 (en) 2020-01-28 2021-08-05 Ariel Scientific Innovations Ltd. Methods of analyzing cell membranes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) * 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5215927A (en) * 1986-01-30 1993-06-01 Fred Hutchinson Cancer Research Center Method for immunoselection of cells using avidin and biotin
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6017719A (en) * 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US20010008766A1 (en) * 1998-03-17 2001-07-19 Sylvia Daunert Quantitative binding assays using green fluorescent protein as a label
US6589503B1 (en) * 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US7198930B2 (en) * 2000-02-29 2007-04-03 Millennium Pharmaceuticals, Inc. Human protein kinase, phosphatase, and protease family members and uses thereof
JP5398945B2 (ja) * 2001-04-23 2014-01-29 マリンクロッド エルエルシー TcおよびRe標識放射活性グリコシル化オクトレオチド誘導体
US20040265921A1 (en) * 2003-06-30 2004-12-30 National University Of Singapore Intein-mediated attachment of ligands to proteins for immobilization onto a support
US7956165B2 (en) * 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest

Also Published As

Publication number Publication date
IL157086A0 (en) 2004-02-08
US20060121519A1 (en) 2006-06-08
JP2007515384A (ja) 2007-06-14
KR20060037337A (ko) 2006-05-03
WO2005010141A3 (en) 2009-03-26
SG145760A1 (en) 2008-09-29
ZA200600315B (en) 2007-04-25
EP1648995A4 (en) 2010-03-10
CN101415721A (zh) 2009-04-22
IL173107A0 (en) 2006-06-11
RU2006105648A (ru) 2006-07-27
MXPA06000944A (es) 2006-03-30
EP1648995A2 (en) 2006-04-26
WO2005010141A2 (en) 2005-02-03
NO20060400L (no) 2006-03-27

Similar Documents

Publication Publication Date Title
US7956165B2 (en) Compositions and methods for purifying and crystallizing molecules of interest
Turkova Oriented immobilization of biologically active proteins as a tool for revealing protein interactions and function
AU2016369524B2 (en) C-terminal lysine conjugated immunoglobulins
EP1370574B1 (en) Sequentially arranged streptavidin-binding modules as affinity tags
WO2005010141A2 (en) Compositions for purifying and crystallizing molecules of interest
JPH05508701A (ja) 被分析物に結合するリガンドの同定方法
JPH032560A (ja) 新規なクロマトグラフィー用固定担体
WO2019204508A1 (en) Systems and method for detection of analytes in high volumetric flow applications
CN118804983A (zh) 含Fc分子的制造方法
EP1813948A1 (en) Method of detecting target substances
EP1856528A2 (en) Compositions and methods for purifying and crystallizing molecules of interest
JP5550797B2 (ja) ヒト心筋由来トロポニンiに特異的にかつ速やかに結合できる変異体タンパク質
EP3755796B1 (en) Method for the preparation of nanoscale dna-encircled lipid bilayers
CN110117312B (zh) 脂质结合蛋白-抗原捕获模块复合物、及其制备方法和应用
AU2006200118A1 (en) Compositions and Methods for Purifying and Crystallizing Molecules of Interest
US9914757B2 (en) Methionyl tRNA synthetase for biosynthesis of photomethionine-labeled protein and method for preparing photoactive protein G variant using same
AU2007203370A1 (en) Compositions and Methods for Purifying and Crystallizing Molecules of Interest
US20140046035A1 (en) Improved production of anti-peptide antibodies
Mohr et al. Immunosorption techniques: fundamentals and applications
Hiruma-Shimizu et al. Deuterated Detergents for Structure-Function Analysis of Membrane Proteins in Solution Using Nuclear Magnetic Resonance (NMR) Spectroscopy and Small-Angle Neutron Scattering (SANS)
JP4735954B2 (ja) 抗体産生キャリア
CN120173117A (zh) 一种识别snd1相分离信号的工程化人源荧光直标抗体及制备
Kassa Production, characterization, and applications of stereoselective antibodies to α-hydroxy acids
CA2708836A1 (en) Methods for purifying or depleting molecules or cells of interest
JPH02216459A (ja) ハプテンである抗原に対し高親和性を持つ抗体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued